OTCMKTS:RGBP

Regen BioPharma Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
0.01
0.06
52-Week Range N/A
Volume31.84 million shs
Average Volume207.31 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive RGBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Regen BioPharma and its competitors with MarketBeat's FREE daily newsletter.


Regen BioPharma logo

About Regen BioPharma

Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1960th out of 2,101 stocks

Biotechnology Industry

78th out of 89 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Regen BioPharma (OTCMKTS:RGBP) Frequently Asked Questions

What stocks does MarketBeat like better than Regen BioPharma?

Wall Street analysts have given Regen BioPharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regen BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Regen BioPharma?

Regen BioPharma saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 110,900 shares, an increase of 128.2% from the May 13th total of 48,600 shares. Based on an average trading volume of 114,450,000 shares, the days-to-cover ratio is presently 0.0 days.
View Regen BioPharma's Short Interest
.

Who are Regen BioPharma's key executives?

Regen BioPharma's management team includes the following people:
  • Dr. David Raymond Koos, Chairman, CEO, Pres, Sec. & Treasurer (Age 60, Pay $180k)

Who are some of Regen BioPharma's key competitors?

What is Regen BioPharma's stock symbol?

Regen BioPharma trades on the OTCMKTS under the ticker symbol "RGBP."

How do I buy shares of Regen BioPharma?

Shares of RGBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does Regen BioPharma have?

Regen BioPharma employs 1 workers across the globe.

What is Regen BioPharma's official website?

The official website for Regen BioPharma is www.regenbiopharmainc.com.

How can I contact Regen BioPharma?

The company can be reached via phone at 619-702-1404.


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.